David W Sant1, Rebecca L Margraf1, David A Stevenson2, Allie H Grossmann3, David H Viskochil4, Heather Hanson4, Melanie D Everitt4, Jonathan J Rios5, Florent Elefteriou6, Theresa Hennessey7, Rong Mao3. 1. ARUP Laboratories, ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, Utah, USA. 2. Department of Pediatrics, Division of Medical Genetics, Stanford University, Stanford, California, USA Departments of Pediatrics, Division of Medical Genetics, University of Utah, School of Medicine, Salt Lake City, Utah, USA Shriners Hospital for Children Salt Lake City, Salt Lake City, Utah, USA. 3. ARUP Laboratories, ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, Utah, USA Department of Pathology, University of Utah, School of Medicine, Salt Lake City, Utah, USA. 4. Departments of Pediatrics, Division of Medical Genetics, University of Utah, School of Medicine, Salt Lake City, Utah, USA. 5. Sarah M. and Charles E. Seay Center for Musculoskeletal Research, Texas Scottish Rite Hospital for Children, Dallas, Texas, USA Department of Pediatrics, UT Southwestern Medical Center, Dallas, Texas, USA Eugene McDermott Center for Human Growth and Development and UT Southwestern Medical Center, Dallas, Texas, USA Department of Orthopaedic Surgery, UT Southwestern Medical Center, Dallas, Texas, USA. 6. Vanderbilt Center for Bone Biology; Vanderbilt University Medical Center, Nashville, Tennessee, USA Departments of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA Departments of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee, USA Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, Tennessee, USA. 7. Shriners Hospital for Children Salt Lake City, Salt Lake City, Utah, USA.
Abstract
BACKGROUND: Tibial pseudarthrosis is associated with neurofibromatosis type 1 (NF1) and there is wide clinical variability of the tibial dysplasia in NF1, suggesting the possibility of genetic modifiers. Double inactivation of NF1 is postulated to be necessary for the development of tibial pseudarthrosis, but tissue or cell of origin of the 'second hit' mutation remains unclear. METHODS: Exome sequencing of different sections of surgically resected NF1 tibial pseudarthrosis tissue was performed and compared to germline (peripheral blood). RESULTS: A germline NF1 splice site mutation (c.61-2A>T, p.L21 M68del) was identified from DNA extracted from peripheral blood. Exome sequencing of DNA extracted from tissue removed during surgery of the tibial pseudarthrosis showed a somatic mutation of NF1 (c.3574G>T, p.E1192*) in the normal germline allele. Further analysis of different regions of the tibial pseudarthrosis sample showed enrichment of the somatic mutation in the soft tissue within the pseudarthrosis site and absence of the somatic mutation in cortical bone. In addition, a germline variant in PTPN11 (c.1658C>T, p.T553M), a gene involved in the RAS signal transduction pathway was identified, although the clinical significance is unknown. CONCLUSIONS: Given that the NF1 somatic mutation was primarily detected in the proliferative soft tissue at the pseudarthrosis site, it is likely that the second hit occurred in mesenchymal progenitors from the periosteum. These results are consistent with a defect of differentiation, which may explain why the mutation is found in proliferative cells and not within cortical bone tissue, as the latter by definition contains mostly mature differentiated osteoblasts and osteocytes. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
BACKGROUND:Tibial pseudarthrosis is associated with neurofibromatosis type 1 (NF1) and there is wide clinical variability of the tibial dysplasia in NF1, suggesting the possibility of genetic modifiers. Double inactivation of NF1 is postulated to be necessary for the development of tibial pseudarthrosis, but tissue or cell of origin of the 'second hit' mutation remains unclear. METHODS: Exome sequencing of different sections of surgically resected NF1tibial pseudarthrosis tissue was performed and compared to germline (peripheral blood). RESULTS: A germline NF1 splice site mutation (c.61-2A>T, p.L21 M68del) was identified from DNA extracted from peripheral blood. Exome sequencing of DNA extracted from tissue removed during surgery of the tibial pseudarthrosis showed a somatic mutation of NF1 (c.3574G>T, p.E1192*) in the normal germline allele. Further analysis of different regions of the tibial pseudarthrosis sample showed enrichment of the somatic mutation in the soft tissue within the pseudarthrosis site and absence of the somatic mutation in cortical bone. In addition, a germline variant in PTPN11 (c.1658C>T, p.T553M), a gene involved in the RAS signal transduction pathway was identified, although the clinical significance is unknown. CONCLUSIONS: Given that the NF1 somatic mutation was primarily detected in the proliferative soft tissue at the pseudarthrosis site, it is likely that the second hit occurred in mesenchymal progenitors from the periosteum. These results are consistent with a defect of differentiation, which may explain why the mutation is found in proliferative cells and not within cortical bone tissue, as the latter by definition contains mostly mature differentiated osteoblasts and osteocytes. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Entities:
Keywords:
PTPN11; bone; neurofibromatosis type 1; pseudarthrosis; somatic mutation
Authors: Rebecca L Margraf; Chad VanSant-Webb; Rong Mao; David H Viskochil; John Carey; Heather Hanson; Jacques D'Astous; Allie Grossmann; David A Stevenson Journal: J Mol Neurosci Date: 2019-02-18 Impact factor: 3.444
Authors: Rebecca L Margraf; Chad VanSant-Webb; David Sant; John Carey; Heather Hanson; Jacques D'Astous; Dave Viskochil; David A Stevenson; Rong Mao Journal: J Mol Diagn Date: 2017-05 Impact factor: 5.568
Authors: Mary J Gray; Peter Kannu; Swarkar Sharma; Christine Neyt; Dongping Zhang; Nandina Paria; Philip B Daniel; Heather Whetstone; Hans-Georg Sprenger; Philipp Hammerschmidt; Angela Weng; Lucie Dupuis; Rebekah Jobling; Roberto Mendoza-Londono; Michael Dray; Peiqiang Su; Megan J Wilson; Raj P Kapur; Edward F McCarthy; Benjamin A Alman; Andrew Howard; Gino R Somers; Christian R Marshall; Simon Manners; Adrienne M Flanagan; Karl E Rathjen; Lori A Karol; Haemish Crawford; David M Markie; Jonathan J Rios; Carol A Wise; Stephen P Robertson Journal: Am J Hum Genet Date: 2015-12-03 Impact factor: 11.025
Authors: S D Ulusal; H Gürkan; E Atlı; S A Özal; M Çiftdemir; H Tozkır; Y Karal; H Güçlü; D Eker; I Görker Journal: Balkan J Med Genet Date: 2017-06-30 Impact factor: 0.519
Authors: Yun Ma; Andrea M Gross; Eva Dombi; Alexander Pemov; Kwangmin Choi; Katherine Chaney; Steven D Rhodes; Steven P Angus; Noah Sciaky; D Wade Clapp; Nancy Ratner; Brigitte C Widemann; Jonathan J Rios; Florent Elefteriou Journal: Genet Med Date: 2020-06-30 Impact factor: 8.864